心力衰竭中的empagliflozin:区域脏处理效应
Veena S Rao1, Juan B Ivey-Miranda1,2, Zachary L Cox3,4
1Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut.
Journal of the American Society of Nephrology : JASN
|December 11, 2023
概括
像empagliflozin这样的-葡萄糖共传输体-2 抑制剂 (SGLT2i) 显著改变了的处理,减少了近道管的再吸收. 身体会补偿,但慢性使用会导致亨尔环和近端管道的适应.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 药理学 药理学是指药理学的学科.
- 心血管医学 心血管医学
背景情况:
- -葡萄糖携带载体-2 抑制剂 (SGLT2i) 对人体处理的确切影响尚不清楚.
- 了解这些影响对于阐明SGLT2i.i.的心脏和脏益处至关重要.
研究的目的:
- 调查empagliflozin对人类区域管状处理的影响.
- 确定SGLT2i对近端管道,亨尔环和远端脏中的再吸收的急性和慢性影响.
主要方法:
- 在糖尿病和心力衰竭患者中使用随机,安慰剂控制的交叉研究设计.
- 在基线和empagliflozin的14天后使用微分分泌 (FELi) 评估区域处理.
- 在亨勒循环中使用布米坦化物来对抗再吸收.
主要成果:
- 恩帕格利弗洛辛显著降低了近端管道中的再吸收,这表明FELi显著增加.
- 急性给药导致在亨尔环和远端脏中进行补偿性再吸收.
- 14天后,由于近道管和/或亨勒环中的再吸收增加,尿素减少.
结论:
- 恩帕格利弗洛辛会诱导内处理的显著重新分配.
- 急性远端补偿平衡增加了近端管道的输送,有助于SGLT2i安全.
- 慢性适应包括在亨尔环和/或近位管管中增加的再吸收,解释了减弱的尿素效应.
更多相关视频
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
436
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
436
Heart Failure Drugs: Diuretics
395
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
395
Heart Failure Drugs: Inotropic Agents
594
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
594
Heart Failure Drugs: β-Blockers
341
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
341
Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Antihypertensive Drugs: Potassium-Sparing Diuretics
578
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
578


